Evaluation of a Novel Tumor Vaccine in Dogs with Hemangiosarcoma
The DOI matches its Crossref record.
Abstract
Background: Hemangiosarcoma (HSA) is a highly metastatic and often rapidly fatal tumor of dogs. At present, adjuvant chemotherapy is the only proven effective treatment for dogs with HSA, though the benefits from chemotherapy are modest. Administration of immunotherapy together with chemotherapy has also been reported to improve survival in dogs with HSA. Therefore, we evaluated safety and immunologic responses to a novel tumor vaccine administered together with doxorubicin chemotherapy in dogs with different stages of HSA. Hypothesis: That tumor vaccination could be safely and effectively combined with doxorubicin chemotherapy for treatment of dogs with HSA. Animals: Twenty-eight dogs with various stages of HSA were enrolled in the study. Methods: The HSA vaccine was prepared with lysates of allogeneic canine HSA cell lines mixed with an adjuvant composed of liposome-DNA complexes. Dogs received a series of 8 immunizations administered over a 22-week period, and most also received chemotherapy. Clinical adverse effects were noted, immune responses were measured by enzyme-linked immunosorbent assay (ELISA) and flow cytometry, and survival times were calculated. Results: The most common adverse effects observed in vaccinated dogs also treated with doxorubicin chemotherapy were diarrhea and anorexia. Vaccinated dogs were found to mount strong humoral immune responses against a control antigen and, most dogs also mounted antibody responses against canine HSA cells. Thirteen dogs with stage II splenic HSA that received the tumor vaccine plus doxorubicin chemotherapy had an overall median survival time of 182 days. Conclusions: We conclude that an allogeneic tumor lysate vaccine is safe in dogs with HSA and can elicit humoral immune responses in dogs that are receiving concurrent doxorubicin chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A Role for Dogs in Advancing Cancer Immunotherapy Research
Dow, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02935 · Cited by 110
Self-citationCanine Cancer: Strategies in Experimental Therapeutics
Thamm, D. H. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01257 · Cited by 38
Self-citationTumor-associated macrophages: Prognostic and therapeutic targets for cancer in humans and dogs
Brady, R. V., & Thamm, D. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1176807 · Cited by 35
Self-citation
Metadata
- Authors
- U'Ren, L. W., Biller, B. J., Elmslie, R. E., Thamm, D. H., & Dow, S. W.
- Venue
- Journal of Veterinary Internal Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-01-01
- Volume
- 21
- Issue
- 1
- Pages
- 113-120
- ISSN
- 0891-6640 (ISSN-L)
- 1939-1676
- OpenAlex
- W4248089092
- Cited by
- 86
- References
- 0
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of a Novel Tumor Vaccine in Dogs with Hemangiosarcoma. https://app.cochat.ai/papers/10.1111/j.1939-1676.2007.tb02936.x
- The paper
- U'Ren, L. W., Biller, B. J., Elmslie, R. E., Thamm, D. H., & Dow, S. W. (2007). Evaluation of a Novel Tumor Vaccine in Dogs with Hemangiosarcoma. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/j.1939-1676.2007.tb02936.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.